Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 11/20 | 0.73 |
| ▸ | ESR1 | P03372 | 12/20 | 0.71 |
| ▸ | ESR2 | Q92731 | 9/20 | 0.71 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.71 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.71 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.71 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.71 |
| ▸ | LMNA | P02545 | 2/20 | 0.68 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.68 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.68 |
| ▸ | MEN1 | O00255 | 1/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.68 |
| ▸ | TP53 | P04637 | 1/20 | 0.68 |
| ▸ | MAPT | P10636 | 1/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.68 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.68 |
| ▸ | PLD2 | O14939 | 1/20 | 0.68 |
| ▸ | ESRRB | O95718 | 1/20 | 0.68 |
| ▸ | PGR | P06401 | 1/20 | 0.68 |
| ▸ | ESRRG | P62508 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12468690 | 1.00 | CYP19A1 (0.73) | CYP19A1ESR1ESR2CYP3A4CYP1A2 | |
| SCHEMBL641722 | 1.00 | CYP19A1 (0.73) | CYP19A1ESR1ESR2CYP3A4CYP1A2 | |
| SCHEMBL18284481 | 0.93 | CYP19A1 (0.64) | CYP19A1ESR1ESR2CYP3A4CYP1A2 | |
| SCHEMBL18284478 | 0.93 | CYP19A1 (0.64) | CYP19A1ESR1ESR2CYP3A4CYP1A2 | |
| SCHEMBL12134458 | 0.92 | CYP19A1 (0.67) | CYP19A1ESR1ESR2CYP3A4CYP1A2 | |
| SCHEMBL23727875 | 0.91 | CYP1A2 (0.71) | CYP19A1ESR1ESR2CYP3A4CYP1A2 | |
| SCHEMBL5493820 | 0.91 | CYP1A2 (0.71) | CYP19A1ESR1ESR2CYP3A4CYP1A2 | |
| SCHEMBL8653836 | 0.89 | PDE1A (0.67) | CYP19A1ESR1ESR2CYP3A4 | |
| SCHEMBL8653838 | 0.89 | PDE1A (0.67) | CYP19A1ESR1ESR2CYP3A4 | |
| SCHEMBL17787470 | 0.88 | CYP19A1 (0.77) | CYP19A1ESR1ESR2CYP3A4CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2016196342-A1 | TETRASUBSTITUTED ALKENE COMPOUNDS AND THEIR USE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2016-12-08 | — | — | WO | disclosed |
| WO-2012050263-A1 | NOVEL METHOD OF PREPARING ENDOXIFEN | CJ CHEILJEDANG CORP. (KR) | 2012-04-19 | — | — | WO | disclosed |
| US-8119695-B2 | Compounds and methods for treating breast cancer and other diseases | CITY OF HOPE (US) | 2012-02-21 | — | — | US | disclosed |
| US-20090176305-A1 | COMPOUNDS AND METHODS FOR TREATING BREAST CANCER AND OTHER DISEASES | CITY OF HOPE | 2009-07-09 | — | — | US | disclosed |
| US-7531578-B2 | Acetic acid 4-{1-[4-(2-dimethylamino-ethoxy)-phenyl]-2-phenyl-but-1-enyl}-phenyl ester; estrogen related receptor (ERR beta or ERR gamma) antagonist; thirty times more effective than 4-hydroxytamoxifen | CITY OF HOPE (US) | 2009-05-12 | — | — | US | disclosed |
| US-20050096384-A1 | Compounds and methods for treating breast cancer and other diseases | CITY OF HOPE | 2005-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050096384-A1 | Compounds and methods for treating breast cancer and other diseases | ESRRB, ESRRG, ESRRA | CYP19A1 9/4885ESR1 7/4885ESR2 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.